https://www.medpagetoday.com/rheumatology/backpain/86469
IL-17A Blockers Succeed in Spine Disease
— Secukinumab and ixekizumab best placebo for ankylosing spondylitis
Ankylosing Spondylitis Treatment Report
www.AnkylosingSpondylitisTreatmentReport.com
https://www.medpagetoday.com/rheumatology/backpain/86469
IL-17A Blockers Succeed in Spine Disease
— Secukinumab and ixekizumab best placebo for ankylosing spondylitis
https://clinicaltrials.gov/ct2/show/NCT03259074?type=Intr&cond=ankylosing+spondylitis&phase=0124&lupd_s=09%2F24%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
DESCRIPTION:
Condition: Ankylosing Spondylitis
Interventions: Biological: Secukinumab; Biological: GP2017 (adalimumab biosimilar)
Sponsor: Novartis Pharmaceuticals
Recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT03259074
FIRST POSTED:
Wed, 23 Aug 2017 12:00:00 EDT
LAST UPDATE POSTED:
10/08/19 08:16AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03259074?type=Intr&cond=ankylosing+spondylitis&phase=0124&lupd_s=09%2F24%2F2019&lupd_d=14&sort=nwst
https://www.rheumatologynetwork.com/news/fda-approves-label-update-secukinumab-ankylosing-spondylitis
FDA Approves Label Update for Secukinumab in Ankylosing Spondylitis
Katie Robinson
February 29, 2020
https://www.biospace.com/article/novartis-eyes-new-cosentyx-approval-after-positive-phase-iii-axial-spondyloarthritis-trial/
Novartis Eyes New Cosentyx Approval After Positive Axial Spondyloarthritis Trial
https://clinicaltrials.gov/ct2/show/NCT03259074